A Pfizer-BioNTech COVID-19 vaccine booster in children ages 5-11 years significantly increased neutralizing antibody titers against the omicron variant with no new safety concerns, according to new data from the manufacturers.
“These data reinforce the potential function of a third dose of the vaccine in maintaining high levels of protection against the virus in this age group,” the companies said in a news release.
The data have not been formally peer reviewed or published in a journal. They are based on clinical trials with 140 children who received a 10-microgram booster six months after their two-dose primary series. The dose is one-third of the adolescent and adult dose.
Read more about the Pfizer-BioNTech COVID-19 vaccine booster in children ages 5-11 years here.